secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019679
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss $9.0M; cash $16.6M; Phase 2 vaping cessation data positive; Phase 3 ORCA-3 topline due Q2
--------------------------------------------------------------------------------

- Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.
- Phase 2 ORCA-V1 trial: cytisinicline 31.8% quit rate vs placebo 15.1%; 2.6x odds (p=0.035).
- Phase 3 ORCA-3 trial (792 adults) fully enrolled; topline results expected Q2 2023.
- Three new board members appointed: Stuart Duty, Thomas King, and Tom Sellig.
- Shares outstanding: 18,040,760 as of May 9, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/0000950170-23-019679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/achv-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer